<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AB28FFD0-BF24-463C-A3F1-27E8DF99B613"><gtr:id>AB28FFD0-BF24-463C-A3F1-27E8DF99B613</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Trembath</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CA071B8B-ECA6-47E7-B59D-85B769844B78"><gtr:id>CA071B8B-ECA6-47E7-B59D-85B769844B78</gtr:id><gtr:firstName>Joanna</gtr:firstName><gtr:surname>Pepke-Zaba</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2FFDB84E-8828-4955-88F5-C99EDB4F8B8E"><gtr:id>2FFDB84E-8828-4955-88F5-C99EDB4F8B8E</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Morrell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502091"><gtr:id>F73E3981-2165-4292-96A6-98A26C8DD22E</gtr:id><gtr:title>Platelet-derived growth factor inhibition in idiopathic and familial pulmonary arterial hypertension</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502091</gtr:grantReference><gtr:abstractText>Pulmonary arterial hypertension is an unusual but devastating condition. It typically affects young women who present with increasing breathlessness on exertion and leads to death within a few years from diagnosis. Current therapies can give some improvement in symptoms but most patients eventually die of the disease. Recent advances in our understanding of the genetic and molecular basis of pulmonary arterial hypertension have identified some key growth factor pathways which are abnormal in the lung blood vessels of these patients. Amongst these, the platelet-derived growth factor (PDGF) pathway shows promise as a new target for treatment. Orally available and well tolerated drugs already exist which target this pathway in other diseases. We propose to study the therapeutic potential of a drug which inhibits the PDGF pathway in patients with severe pulmonary hypertension. In addition, we will undertake studies in cells derived from these patients to increase our understanding of how this drug works in pulmonary hypertension.</gtr:abstractText><gtr:technicalSummary>Pulmonary arterial hypertension (PAH) is a devastating condition which affects predominantly women of child-bearing age. Death typically ensues from right heart failure within 3 years without modern treatments. Available treatments improve symptoms of breathlessness but survival remains poor. Mutations in the gene encoding the bone morphogenetic protein type II receptor (BMPR-II) underlie 70% of cases of familial PAH, and 25% of apparently ?sporadic? cases of PAH. Our group, and others, have provided evidence that dysfunctional BMP signalling underlies various forms of severe PAH. These genetic findings have suggested a critical role for the BMP/TGF-beta superfamily in the pathogenesis of severe PAH. Our laboratories have shown that missense mutations in the functional domains of BMPR-II reduce the efficiency of Smad1 activation and the transcription of BMP responsive genes. In addition, suppression of BMP signalling allows exaggerated growth responses to transforming growth factor-beta (TGF-beta). Our preliminary data suggest that the exaggerated growth response to TGF-beta in mutant cells occurs via activation of platelet-derived growth factor (PDGF) receptors. Animal studies in rat models of PAH, and a single case study in man, have shown that the orally available PDGF receptor kinase inhibitor, imatinab, can reverse established pulmonary hypertension. This drug is currently licensed for the treatment of chronic myeloid leukaemia and is generally well tolerated. This proposal seeks to demonstrate in a proof of concept study whether a 6 month trial of imatinib versus placebo demonstrates safety and efficacy in the treatment of severe pulmonary arterial hypertension. In addition, we propose to demonstrate the molecular basis of the PDGF-dependent proliferation in relevant cells derived patients with idiopathic and familial PAH. To undertake these mechanistic studies we have established techniques to derive endothelial progenitor cells (EPCs) from patients and controls. The BMPR-II mutation status of all samples will be determined. Both early and late outgrowth EPCs will be characterised and used for in vitro studies of cell proliferation, tube formation and migration. BMP/TGF-beta signalling pathways and PDGF ligand and receptor expression and signalling will be determined. The mechanism of action of imatinib will also be investigated in these cells. This study will provide novel mechanistic insight into the pathogenesis of PAH. The proof of concept trial will be the first targeted growth factor therapy in severe PAH and may provide evidence for efficacy of this approach in man.</gtr:technicalSummary><gtr:fund><gtr:end>2009-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>308108</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>EU Framework 6 &amp;quot;PULMOTENSION&amp;quot;</gtr:description><gtr:id>4B895079-EEB7-4ED1-A32B-4E4F378A0EC5</gtr:id><gtr:impact>Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, Schermuly RT, Morrell NW.Smad-dependent and Smad-independent induction of ld1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circulation Research 2010 Jun 3 [Epub ahead of print] PMID: 20522807.

Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Luke S, Howard LS, Marchesan D, Yang J, Suntharalingam J, Soon E, Exley A, Stewart S, Hecker M, Zhu Z, Gehling U, Seeger W, Pepke-Zaba J, and Morrell NW. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 2009;180 780-787.</gtr:impact><gtr:outcomeId>AA7AB091141-1</gtr:outcomeId><gtr:partnerContribution>Collaborative studies on endothelial progenitor cells</gtr:partnerContribution><gtr:piContribution>Collaborative studies and expertise with endothelial progenitor cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Fellowship</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>256C67AC-3767-4DED-A7A9-F1C4500E1531</gtr:id><gtr:outcomeId>763C345A7190</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Imatinib was shown to be effective in severe PAH in the MRC sponsored experimental medicine study. the subsequent phase 3 study showed benefit but due to the side effect profile this is not being developed further by the company (Novartis).</gtr:description><gtr:id>062646F9-7104-4D41-90AB-DEE7A370370E</gtr:id><gtr:impact>The study demonstrated that tyrosine kinase inhibition might be a useful approach in this rare and often fatal disease. Unfortunately the side effect profile was not favourable. Further studies will focus on more selective tyrosine kinases.</gtr:impact><gtr:outcomeId>go8ggbx7rXS</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Imatinib</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.novartis.com</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Late outgrowth EPCs from controls and patients with pulmonary arterial hypertension</gtr:description><gtr:id>0BF52F60-D743-4191-A2E5-66BF79CD04E5</gtr:id><gtr:impact>Availability of EPC s from patients with defined mutations in BMPR2 gene in familial pulmonary hypertension</gtr:impact><gtr:outcomeId>D8F8ED51A3A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Endothelial progenitor cells</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>81572B9D-65D9-4527-B609-A9D8D7980C35</gtr:id><gtr:title>Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11e74e5a3a7b3794a49aa81194f3c27f"><gtr:id>11e74e5a3a7b3794a49aa81194f3c27f</gtr:id><gtr:otherNames>Zhao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>pm_13266_26_22117534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4976C6D3-4136-4E2D-B1CA-3723CAE38658</gtr:id><gtr:title>Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor.</gtr:title><gtr:parentPublicationTitle>Chest</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0f9b47ac3b2fc45ec46903e0836310"><gtr:id>5d0f9b47ac3b2fc45ec46903e0836310</gtr:id><gtr:otherNames>Davies RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-3692</gtr:issn><gtr:outcomeId>pm_13266_16_19059957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6230008-2D1F-4CF0-A35C-9A57302F3D4B</gtr:id><gtr:title>Endothelial progenitor cells in pulmonary hypertension - dawn of cell-based therapy?</gtr:title><gtr:parentPublicationTitle>International journal of clinical practice. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d937f5f0be2511cd86725eea834e5c4c"><gtr:id>d937f5f0be2511cd86725eea834e5c4c</gtr:id><gtr:otherNames>Toshner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1368-504X</gtr:issn><gtr:outcomeId>pm_13266_16_19958395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84751AFA-D84C-43BE-AFBB-A05D6DB036D5</gtr:id><gtr:title>Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46db63962c3ff7c7b7e659919300d201"><gtr:id>46db63962c3ff7c7b7e659919300d201</gtr:id><gtr:otherNames>Hoeper MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>JmBTn9vtnoc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>953AB258-ED25-455D-9F31-D9821BC9F4A9</gtr:id><gtr:title>Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5f2b205447531f69d66d0825735927d"><gtr:id>c5f2b205447531f69d66d0825735927d</gtr:id><gtr:otherNames>Frost AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1053-2498</gtr:issn><gtr:outcomeId>56b0a13c74a572.34265553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9143929D-51A3-47DD-851E-F69A0CDB5170</gtr:id><gtr:title>Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ab92ac7e6da90d16652ebd20a383d15"><gtr:id>2ab92ac7e6da90d16652ebd20a383d15</gtr:id><gtr:otherNames>Ghofrani HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>T1GrgLgVmD5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8208D7D3-1F43-4F7B-81E9-F6F1837E9989</gtr:id><gtr:title>The fibrocyte in pulmonary hypertension: we seek him here, we seek him there.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0ca8637fc56144623b946d1038b3c86"><gtr:id>a0ca8637fc56144623b946d1038b3c86</gtr:id><gtr:otherNames>Toshner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_13266_26_22210809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECDB22EF-F89A-4614-9FF1-AF3B4FADA300</gtr:id><gtr:title>Regulation of bone morphogenetic protein signalling in human pulmonary vascular development.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b45508270955df58655c3dcef05dea36"><gtr:id>b45508270955df58655c3dcef05dea36</gtr:id><gtr:otherNames>Southwood M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_13266_16_17992660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A63D8C2F-DE81-402A-A9B1-C1406D3A8307</gtr:id><gtr:title>Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d937f5f0be2511cd86725eea834e5c4c"><gtr:id>d937f5f0be2511cd86725eea834e5c4c</gtr:id><gtr:otherNames>Toshner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>D3C0BEE19D1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502091</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>